Prescribing Trends of Adjuvant Neratinib in Hormone Receptor-Positive HER2-Positive Breast Cancer
High-risk clinical features significantly influenced neratinib prescribing. Residual disease did not appear to impact prescribing decisions. These findings suggest biologic risk criteria may serve as practical guidelines for adjuvant neratinib use.
Authors
- Hulya Kocyigit (ORCID: https://orcid.org/0000-0003-1862-7867)
- Amy Tiersten (ORCID: https://orcid.org/0000-0002-4054-9140)
- Julia Blanter (ORCID: https://orcid.org/0000-0002-2682-5719)
- Lakshmi Kowtha
- Malini Harigopal
Institutions
- Karamanoğlu Mehmetbey University (TR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Oncology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1159/000549970
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00